Publications by authors named "Susan Soto"

Claim this Profile
A
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.
Andy Itsara, Victoria M Rogness, Laura Samples, Constance M Yuan, Hao-Wei Wang, Susan Soto

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.
Rui Mu, Katherine M Hornick, Neelam Redekar, Jonathan Chen, Pia Nierman, Susan Soto

J Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells.
Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, Elizabeth J Carstens, Margaret A Lindorfer, Susan Soto

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Susan Soto

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.
Christopher Pleyer, Kerry J Laing, Mir A Ali, Christopher L McClurkan, Susan Soto

Blood Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.
Sanjal Desai, Clifton Mo, Erika M Gaglione, Constance M Yuan, Maryalice Stetler-Stevenson, Susan Soto

Leuk Lymphoma· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
Inhye E Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, Susan Soto

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Christopher Pleyer, Mir A Ali, Jeffrey I Cohen, Xin Tian, Susan Soto

Blood· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Christopher Pleyer, Xin Tian, Shakuntala Rampertaap, Rui Mu, Susan Soto

Am J Hematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Christopher Pleyer, Clare Sun, Sanjal Desai, Inhye E Ahn, Xin Tian, Susan Soto

Leuk Lymphoma· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Inhye E Ahn, Neil Basumallik, Xin Tian, Susan Soto, Adrian Wiestner

Blood· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Georg Aue, Clare Sun, Delong Liu, Jae-Hyun Park, Stefania Pittaluga, Susan Soto

J Immunol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Inhye E Ahn, Mohammed Z H Farooqui, Xin Tian, Janet Valdez, Clare Sun, Susan Soto

Blood· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
Thomas M Herndon, Shih-Shih Chen, Nakhle S Saba, Janet Valdez, Claire Emson, Susan Soto

Leukemia· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, Sarah E M Herman, Xin Tian, Susan Soto

Blood· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myoblast replication is reduced in the IUGR fetus despite maintained proliferative capacity in vitro.
Susan M Soto, Amy C Blake, Stephanie R Wesolowski, Paul J Rozance, Kristen B Barthel

J Endocrinol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Carole Bitar, Mohammed Z H Farooqui, Janet Valdez, Nakhle S Saba, Susan Soto

JAMA Dermatol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Martin Skarzynski, Carsten U Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Maric, Susan Soto

Clin Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Andrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, Sabrina Martyr, Ann M Cullinane, Susan Soto

Haematologica· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
Clare Sun, Xin Tian, Yuh Shan Lee, Sreenivasulu Gunti, Andrew Lipsky, Susan Soto

Blood· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Mohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, Georg Aue, Nakhle Saba, Susan Soto

Lancet Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Matthew J Olnes, Phillip Scheinberg, Katherine R Calvo, Ronan Desmond, Yong Tang, Susan Soto

N Engl J Med· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
Georg Aue, Jay Nelson Lozier, Xin Tian, Ann M Cullinane, Susan Soto

Am J Hematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Georg Aue, Ndegwa Njuguna, Xin Tian, Susan Soto, Thomas Hughes

Haematologica· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis